- Home
- NIKI vs BCAB Comparison
NIKI vs BCAB Comparison
Compare NIKI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$7.82
HOLD
Current Price
$3.16
Company Overview
Basic Information| Metric | NIKI | BCAB |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.9M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NIKI | BCAB |
|---|---|---|
| Price | $7.82 | $3.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.2K | ★ 47.9K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $0.12 |
| 52 Week High | $10.39 | $6.52 |
Technical Indicators
Market Signals| Indicator | NIKI | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 42.77 |
| Support Level | N/A | $0.17 |
| Resistance Level | $10.00 | $3.71 |
| Average True Range (ATR) | 0.83 | 0.30 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 4.27 | 44.53 |
Price Performance
Historical Comparison NIKI
BCAB
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.